Form 4: ARVINAS Executive Granted Equity Awards

ARVINAS's VP, Chief Accounting Officer, David K Loomis, received grants of restricted stock units and stock options as part of the company's incentive plan.

Summary

• David K Loomis, VP, Chief Accounting Officer of ARVINAS, INC. (ARVN), was granted 12,420 Restricted Stock Units (RSUs) on February 26, 2026, under the company's 2018 Stock Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock for no consideration.
• The RSUs will vest over four years, with one-quarter vesting on February 26, 2027, and subsequent one-quarter portions vesting on February 26, 2028, February 26, 2029, and February 26, 2030, contingent on continued service.
• Following the RSU transaction, Loomis beneficially owns 42,112 shares of common stock.
• Loomis was also granted 18,504 stock options on February 26, 2026, under the same plan, with an exercise price of $13.38 per share.
• The stock options will vest over four years, with one-quarter vesting on February 26, 2027, and the remainder vesting in equal monthly installments through February 26, 2030, subject to continued service.
• The stock options have an expiration date of February 25, 2036.
• Following the stock option transaction, Loomis beneficially owns 18,504 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive, standard compensation event that aligns executive interests with long-term shareholder value, indicating stability in management incentives.

Positives

• The equity grants align the interests of the VP, Chief Accounting Officer with those of shareholders, promoting long-term value creation.
• The multi-year vesting schedule acts as a retention incentive for a key executive.
• The grants are part of a pre-existing 2018 Stock Incentive Plan, indicating a structured approach to executive compensation.

Future Outlook

The grants of restricted stock units and stock options imply an expectation of continued service from the reporting person, as vesting is contingent on remaining with the Issuer through the specified dates up to February 26, 2030.

Industry Context

StockSavvy.ai notes that equity grants are a common practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key talent. Such compensation structures align executive interests with long-term company performance and shareholder value, which is crucial for companies like ARVINAS focused on drug development and commercialization.

Comparison to Industry Standards

• StockSavvy.ai observes that multi-year vesting schedules for equity awards, such as the four-year schedule detailed for both RSUs and stock options, are standard practice across the biotechnology sector. This approach is consistent with compensation strategies seen at comparable innovative biotech firms like Moderna or BioNTech, ensuring long-term commitment from executives.
• The grant of 'at-the-money' or 'in-the-money' stock options (where the exercise price is set at or above the market price on the grant date) and RSUs (which have inherent value upon vesting) is a common component of executive compensation packages designed to reward future performance and share price appreciation.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and stock options to David K Loomis, a VP and Chief Accounting Officer, constitutes a related party transaction, which is a standard form of executive compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the executive's financial interests with long-term shareholder value creation.
• Employees (Reporting Person): David K Loomis receives significant equity compensation, incentivizing continued performance and retention.

Next Steps

• Vesting of one-quarter of the RSUs and stock options on February 26, 2027, subject to continued service.
• Subsequent annual vesting of RSUs on February 26, 2028, February 26, 2029, and February 26, 2030.
• Monthly vesting of the remaining stock options from February 26, 2027, through February 26, 2030, subject to continued service.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive, which is a standard compensation practice. It does not provide new fundamental information to warrant a change in investment thesis, but rather reinforces management's continued alignment with the company's long-term performance.

Keywords

ARVINAS, ARVN, Form 4, insider transaction, equity grant, restricted stock units, stock options, executive compensation, David K Loomis